Paratek Pharma

Our Product

NUZYRA® is an FDA-approved tetracycline-class antibiotic designed to address a significant unmet need for adult patients with CABP and ABSSSI caused by susceptible bacteria.

About Nuzyra

Groundbreaking Innovators

A disciplined team with proven capabilities in developing and commercializing new treatment options for complex medical issues.
‍

Meet Our Team

Powered by You

Our employees are experienced, committed, and driven to build a company that saves lives. Learn more about how you can join our team.

View Open Roles

Taking on the Challenge of Antimicrobial Resistance (AMR)

"Antimicrobial resistance (AMR) is a critical, global public health issue and an ongoing pandemic. Efforts to combat AMR require a multi-pronged approach, including responsible antibiotic use, improved surveillance, research into new antibiotics, and policy changes to enable a vibrant marketplace that recognizes the life-saving value of novel antibiotics. Paratek is a biopharmaceutical company that is dedicated to addressing AMR, a critical concern for public health and national security."

Evan Loh, M.D. CEO, Paratek

Taking on the Challenge of Antimicrobial Resistance (AMR)

Gaps in pandemic preparedness go beyond the bioterrorism space to resistant-bacteria pathogens and viral infections.

Taking on the Challenge of Antimicrobial Resistance (AMR)

AMR is a deadly health threat that according to recent estimates takes the lives of 160,000 Americans each year. It is an ongoing pandemic that will worsen unless we are able to provide new technologies to defeat superbugs.

Taking on the Challenge of Antimicrobial Resistance (AMR)